Schwab Charles Investment Management Inc. cut its position in shares of Boston Scientific Corporation (NYSE:BSX) by 12.0% during the second quarter, Holdings Channel reports. The firm owned 4,659,573 shares of the medical equipment provider’s stock after selling 634,350 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Boston Scientific Corporation were worth $129,164,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in BSX. BlackRock Inc. boosted its position in shares of Boston Scientific Corporation by 2,181.6% in the first quarter. BlackRock Inc. now owns 95,744,545 shares of the medical equipment provider’s stock worth $2,381,169,000 after buying an additional 91,548,235 shares during the period. FMR LLC boosted its position in shares of Boston Scientific Corporation by 7.6% in the first quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock worth $4,593,698,000 after buying an additional 13,105,596 shares during the period. MARSHALL WACE ASIA Ltd acquired a new position in shares of Boston Scientific Corporation during the first quarter worth $149,859,000. Marshall Wace North America L.P. acquired a new position in shares of Boston Scientific Corporation during the first quarter worth $149,859,000. Finally, Vanguard Group Inc. boosted its position in shares of Boston Scientific Corporation by 4.0% in the first quarter. Vanguard Group Inc. now owns 91,134,744 shares of the medical equipment provider’s stock worth $2,266,521,000 after buying an additional 3,503,965 shares during the period. Hedge funds and other institutional investors own 92.08% of the company’s stock.

Boston Scientific Corporation (NYSE BSX) opened at 26.41 on Friday. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $28.51. The stock has a market cap of $36.24 billion, a P/E ratio of 47.25 and a beta of 1.09. The firm’s 50-day moving average is $27.34 and its 200-day moving average is $26.04.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The firm’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.27 earnings per share. On average, equities analysts forecast that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

WARNING: “Schwab Charles Investment Management Inc. Reduces Position in Boston Scientific Corporation (BSX)” was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/13/schwab-charles-investment-management-inc-reduces-position-in-boston-scientific-corporation-bsx.html.

Several research analysts have commented on the stock. Needham & Company LLC boosted their price target on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 22nd. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Boston Scientific Corporation in a report on Tuesday, May 16th. They set a “neutral” rating and a $28.00 price target for the company. Zacks Investment Research cut shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Finally, BidaskClub cut shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Boston Scientific Corporation currently has an average rating of “Buy” and an average target price of $30.06.

In other Boston Scientific Corporation news, SVP David A. Pierce sold 2,972 shares of the firm’s stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $27.70, for a total value of $82,324.40. Following the sale, the senior vice president now directly owns 28,572 shares in the company, valued at $791,444.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael P. Phalen sold 15,500 shares of the firm’s stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $28.02, for a total value of $434,310.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 236,489 shares of company stock valued at $6,440,888. 0.74% of the stock is currently owned by corporate insiders.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.